US00901B1052
© Globe Newswire
10.12.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
News Preview
Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
AIMI
LISTED
OTC
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
News Preview
OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
News Preview
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
20.10.2025
AIMI
LISTED
OTC
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
News Preview
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.09.2025
AIMI
LISTED
OTC
AIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得
News Preview
この特許は、ライセンス供与、共同研究、長期的な収益成長の機会を提供し、国際市場での保護拡大を目指すAIMの戦略を支えるものである...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
AIMI
LISTED
OTC
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
News Preview
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
AIMI
LISTED
OTC
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
News Preview
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2025
AIMI
LISTED
OTC
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Continued progress across pipeline programs with focus on pancreatic cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
News Preview
OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common stock, and...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
News Preview
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
News Preview
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025 Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
News Preview
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company’s ticker symbol on the...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
07.04.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
News Preview
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.04.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
News Preview
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification fr...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
AIMI
LISTED
OTC
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
News Preview
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
News Preview
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s Plan to regain compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.02.2025
AIMI
LISTED
OTC
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
News Preview
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody generation in humans Planned Investigational New Drug application to expand on previ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2025
AIMI
LISTED
OTC
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
News Preview
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
News Preview
A Plan for Compliance has been Undertaken A Plan for Compliance has been Undertaken...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company’s incumbent directors – Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – to the Board of Directors (the “Board”) at the 2024 Annual Meeting...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024 at 11:00 a.m. ET:
AIM urges shareholders to protect their investment and the Company's future by voting on the...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024:
With the Annual Meeting quickly approaching, it is critical that shareholders vote on the WHITE universal pro...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
News Preview
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 — a compositions and methods patent — covering Ampligen® (rintatolimod) for use in the treatment of the post-COVID condition...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
AIMI
LISTED
OTC
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended that shareholders vote “FOR” Company nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the “Annua...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
News Preview
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
AIMI
LISTED
OTC
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended that shareholders vote “FOR” Company nominees Nancy K. Bryan and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), p...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
AIMI
LISTED
OTC
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, the “Activist Group”) as part of their multi-year attempt to take over AIM’s Board of Directors (the “Board”) at the upco...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech Refutes Activist Group’s False and Misleading Claims
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement refuting the false and misleading claims recently made by a group of activist investors (collectively, the “Activist Group”) relating to their multi-year attempt to take over AIM’s Board of Directors (the “Board”) at the upcoming 2024 Annual Meet...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces Cash Conservation Plan
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Compensation Committee of the Company’s Board of Directors (the “Board”) has established a cash conservation plan (the “Cash Conservation Plan”). The Cash Conservation Plan is a key part of the Board and management team’s efforts to bolster the Company’s abi...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders the (“Annual Meeting”), presently scheduled for December 17, 2024.
Highlights of the presentation include the following:
AIM is executing on its strategy to create long-term value fo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
AIMI
LISTED
OTC
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
News Preview
The Delaware Supreme Court Ruled that the Incumbent Board Breached its Fiduciary Duties to Stockholders
AIM Board Wasted Millions in Furtherance of Improper Purpose
Stockholders Urged to Act Now Before the Board's Self-Interested Behavior Irreversibly Damages the Company
Stockholders Should Not be Fooled by Misleading Statements by AIM Board – Th...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
News Preview
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen® (also known as rintatolimod) as a component of a chemokine-modulating (CKM) regimen in earl...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
News Preview
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
AIMI
LISTED
OTC
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
News Preview
AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming 2024 Annual Meeting of Stockholders, scheduled for December 17, 2024. The Company also mailed a letter to shareholders.
This press releas...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
AIMI
LISTED
OTC
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
News Preview
Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ET Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
AIMI
LISTED
OTC
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
News Preview
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
News Preview
Company is planning a follow-up clinical trial with a focused subject population of moderate-to-severe Post-COVID-related fatigue Company is planning a follow-up clinical trial with a focused subject population of moderate-to-severe Post-COVID-related fatigue...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.08.2024
AIMI
LISTED
OTC
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
News Preview
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
AIMI
LISTED
OTC
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
News Preview
OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
News Preview
OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial in...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2024
AIMI
LISTED
OTC
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
News Preview
OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study of Ampligen and AstraZ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
AIMI
LISTED
OTC
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
News Preview
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2024
AIMI
LISTED
OTC
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
News Preview
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
AIMI
LISTED
OTC
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
